Suhlrie A, Hennies I, Gellermann J, et al. - Using the Lupus Nephritis Registry of the German Society of Paediatric Nephrology, researchers analyzed 79 predominantly Caucasian children with proliferative lupus nephritis (LN), to assess renal outcome as well as treatment toxicity in these pediatric patients treated with intensified immunosuppressive protocols. Inferior renal outcome was noted in relation to nephrotic range proteinuria at the time of diagnosis, whereas non-significant correlates were all other variables including mode of immune-suppressive therapy (e.g., induction treatment with cyclophosphamide (IVCYC) vs mycophenolate mofetil (MMF)). Overall 80% of patients encountered complications, with glucocorticoid toxicity, leukopenia, infection, and menstrual disorder reported in 42%, 37%, 23%, and in 20%, respectively. Findings revealed good renal outcome at 12 months regardless if patients were managed with induction treatment with MMF or IVCYC, however, a high glucocorticoid toxicity was evident suggesting the requirement for corticoid sparing protocols.